SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Shasun surges on successfully completing USFDA inspection at its oral dosage facility

01 Jul 2016 Evaluate

Strides Shasun is currently trading at Rs. 1194.85, up by 66.30 points or 5.87% from its previous closing of Rs. 1128.55 on the BSE.

The scrip opened at Rs. 1178.75 and has touched a high and low of Rs. 1194.85 and Rs. 1160.00 respectively. So far 12,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1412.45 on 23-Nov-2015 and a 52 week low of Rs. 848.00 on 29-Feb-2016.

Last one week high and low of the scrip stood at Rs. 1203.00 and Rs. 1041.00 respectively. The current market cap of the company is Rs. 10,696.00 crore.

The promoters holding in the company stood at 31.14%, while Institutions and Non-Institutions held 46.98% and 21.88% respectively.

Strides Shasun has successfully completed US Food and Drug Administration (USFDA) inspection at its flagship oral dosage facility in Bangalore with ‘Zero 483s’. The audit was carried out related to a product filed from the new semi solids block from where the company has made a series of filings. With the recently closed Establishment Inspection Report (EIR) announced on June 7, 2016, the entire facility is now USFDA compliant.

The oral dosage facility (KRS Gardens facility) in Bangalore manufactures oral dosage forms including tablets, capsules (both hard gelatine and soft gelatine), ointments and liquids. The manufacturing plant supports important current and future submissions for the US Market.

Strides Shasun (formerly known as Strides Arcolab) is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.


Strides Pharma Scien Share Price

997.65 1.75 (0.18%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×